RxDoctor Payments Data

John Mohart, MD

Cardiovascular Disease · Washington, MONPI 1922041987

Payments from drug & device makers

$13,897in general payments, 2019–2025

Across 41 payments — averaging $338.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$13K
  • Johnson & Johnson$294
  • Medtronic$170
  • W. L. Gore & Associates, Inc.$122
  • Abbott$88
  • Lemaitre Vascular, Inc.$47
  • plus $27 from 1 others

What the payments were for

  • Speaking & faculty fees$13,15095%
  • Food & beverage$7475%

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer2$13,150
Johnson & Johnson24$294
Medtronic(2 entities)5$170
W. L. Gore & Associates, Inc.2$122
Abbott5$88
Lemaitre Vascular, Inc.1$47
Novartis2$27

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,897 in reported general payments places this provider in the 75th percentile of 391 cardiovascular disease providers in Missouri.

See all cardiovascular disease providers in Missouri

Medicare billing

Part B allowed, 2024
$4,772
Medicare patients
32
Services billed
50

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban179$167,412
XareltoRivaroxaban48$72,097
Repatha SureclickEvolocumab22$20,931
Atorvastatin Calcium190$1,948
Diltiazem 24hr Er (Cd)Diltiazem Hcl35$1,289
Potassium Chloride57$1,180
Warfarin Sodium75$1,090
Metoprolol Tartrate167$972
Rosuvastatin Calcium71$941
ClopidogrelClopidogrel Bisulfate89$852
Flecainide Acetate13$797
Losartan Potassium44$783
Carvedilol62$590
Isosorbide Mononitrate ErIsosorbide Mononitrate42$567
Amlodipine Besylate90$509

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$13,150$167,412179 claims
Johnson & JohnsonXarelto$294$72,09748 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 391 cardiovascular disease providers in Missouri.

Other cardiovascular disease in Washington

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →